1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Organon Tempers Expectations Ahead Of Adalimumab Second Wave

Firm Prepares To Launch Both High- And Low-Concentration US Humira Biosimilars

 
• By Dave Wallace

Ahead of joining a second wave of Humira biosimilars hitting the US market in just a couple of months, Organon has projected a “modest ramp” in initial sales for its Hadlima version in 2023.

Skate ramp gradually ramping up
Organon expects a “modest ramp” for Hadlima in the US • Source: Shutterstock

With Organon’s Hadlima (adalimumab-bwwd) biosimilar representing just one of many new Humira rivals that is due to hit the US market in a couple of months – as a second wave of competition materializes following Amgen’s debut biosimilar arriving early in 2023 (Also see "Amgen Reveals First Figures For US Humira Rival" - Generics Bulletin, 28 April, 2023.) – the company has set out its expectations for a gradual ramp-up of sales this year ahead of a more significant contribution from Hadlima in 2024 and 2025.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.